Reviewing Genocea Biosciences (NASDAQ:GNCA) and Aziyo Biologics (NASDAQ:AZYO)
Reviewing Genocea Biosciences (NASDAQ:GNCA) and Aziyo Biologics (NASDAQ:AZYO)
Genocea Biosciences (NASDAQ:GNCA – Get Rating) and Aziyo Biologics (NASDAQ:AZYO – Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, earnings, profitability, analyst recommendations, risk and valuation.
基因生物科學(納斯達克：GNCA-GET評級)和阿齊約生物(納斯達克：AZYO-GET評級)都是小盤醫療公司，但哪隻股票更好？我們將根據兩家公司的股息、機構所有權、收益、盈利能力、分析師建議、風險和估值來比較它們的實力。
Analyst Ratings
分析師評級
This is a breakdown of current ratings and recommmendations for Genocea Biosciences and Aziyo Biologics, as reported by MarketBeat.com.
據MarketBeat.com報道，這是對Genocea Biosciences和Aziyo Biologics的當前評級和推薦的細分。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Genocea Biosciences | 0 | 2 | 0 | 0 | 2.00 |
| Aziyo Biologics | 0 | 0 | 3 | 0 | 3.00 |
| 銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
| Genocea生物科學 | 0 | 2 | 0 | 0 | 2.00 |
| Aziyo生物製品 | 0 | 0 | 3 | 0 | 3.00 |
Genocea Biosciences presently has a consensus price target of $3.00, suggesting a potential upside of 26,685.71%. Aziyo Biologics has a consensus price target of $12.00, suggesting a potential upside of 83.21%. Given Genocea Biosciences' higher possible upside, analysts clearly believe Genocea Biosciences is more favorable than Aziyo Biologics.
Genocea Biosciences目前的共識目標價為3.00美元，這意味着潛在的上漲幅度為26,685.71%。Aziyo Biologics的共識目標價為12.00美元，暗示潛在上行空間為83.21%。考慮到Genocea Biosciences更有可能的上行空間，分析師們顯然認為Genocea Biosciences比Aziyo Biologics更有利。
Risk & Volatility
風險與波動性
Profitability
盈利能力
This table compares Genocea Biosciences and Aziyo Biologics' net margins, return on equity and return on assets.
此表比較了Genocea Biosciences和Aziyo Biologics的淨利潤率、股本回報率和資產回報率。
| Net Margins | Return on Equity | Return on Assets | |
| Genocea Biosciences | N/A | -182.88% | -62.76% |
| Aziyo Biologics | -60.68% | -260.23% | -43.50% |
| 淨利潤率 | 股本回報率 | 資產回報率 | |
| Genocea生物科學 | 不適用 | -182.88% | -62.76% |
| Aziyo生物製品 | -60.68% | -260.23% | -43.50% |
Valuation and Earnings
估值和收益
This table compares Genocea Biosciences and Aziyo Biologics' revenue, earnings per share (EPS) and valuation.
此表比較了Genocea Biosciences和Aziyo Biologics的收入、每股收益(EPS)和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Genocea Biosciences | $1.64 million | 0.40 | -$33.20 million | ($0.61) | -0.02 |
| Aziyo Biologics | $47.39 million | 1.87 | -$24.83 million | ($2.46) | -2.66 |
| 總收入 | 價格/銷售額比 | 淨收入 | 每股收益 | 市盈率 | |
| Genocea生物科學 | 164萬美元 | 0.40 | -3320萬美元 | ($0.61) | -0.02 |
| Aziyo生物製品 | 4739萬美元 | 1.87 | -2,483萬元 | ($2.46) | -2.66 |
Aziyo Biologics has higher revenue and earnings than Genocea Biosciences. Aziyo Biologics is trading at a lower price-to-earnings ratio than Genocea Biosciences, indicating that it is currently the more affordable of the two stocks.
Aziyo Biologics的收入和收益比Genocea Biosciences更高。Aziyo Biologics的市盈率低於Genocea Biosciences，這表明它目前是兩隻股票中更負擔得起的一隻。
Insider and Institutional Ownership
內部人與機構持股
59.3% of Genocea Biosciences shares are held by institutional investors. Comparatively, 88.6% of Aziyo Biologics shares are held by institutional investors. 1.6% of Genocea Biosciences shares are held by company insiders. Comparatively, 39.9% of Aziyo Biologics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Genocea Biosciences 59.3%的股份由機構投資者持有。相比之下，Aziyo Biologics 88.6%的股份由機構投資者持有。Genocea Biosciences 1.6%的股份由公司內部人士持有。相比之下，Aziyo Biologics 39.9%的股份由公司內部人士持有。強大的機構持股表明，大型基金管理公司、捐贈基金和對衝基金相信，一隻股票有望實現長期增長。
Summary
摘要
Aziyo Biologics beats Genocea Biosciences on 8 of the 14 factors compared between the two stocks.
在兩隻股票的14個指標中，Aziyo Biologics在8個指標上擊敗了Genocea Bioscions。
About Genocea Biosciences
關於Genocea生物科學
(Get Rating)
(獲取評級)
Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts.
生物製藥公司Genocea Biosciences，Inc.發現和開發新的癌症免疫療法。該公司使用其專有的發現平臺ATLAS，該平臺描述了每個患者對下一代腫瘤測序確定的每個目標或抗原的CD4+和CD8+T細胞免疫反應。它的產品包括Gen-011，這是一種過繼的T細胞療法，正處於治療實體腫瘤的1/2a階段臨牀試驗；以及Gen-009，它是一種新抗原候選疫苗，正處於1/2a階段的臨牀試驗，提供跨越ATLAS識別的抗腫瘤新抗原的輔助性合成長肽。該公司成立於2006年，總部設在馬薩諸塞州劍橋市。
About Aziyo Biologics
關於Aziyo生物製品公司
(Get Rating)
(獲取評級)
Aziyo Biologics, Inc., a regenerative medicine company, focuses on the development of regenerative medical products to address the implantable electronic device/cardiovascular, orthopedic/spinal repair, and soft tissue reconstruction markets. It offers CanGaroo that combines the envelope with antibiotics and is designed to reduce the risk of infection following surgical implantation of an electronic device. The company also provides cardiovascular products, such as ProxiCor for use as an intracardiac patch or pledget for tissue repairs; Tyke for use in neonates and infants to repair pericardial structures; and VasCure, a patch material to repair or reconstruct the peripheral vasculature, including the carotid, renal, iliac, femoral, and tibial blood vessels for cardiovascular, vascular, and general surgeons. In addition, it offers Fiber VBM, ViBone, and OsteGro V that are human tissue-derived bone allografts designed to protect and preserve native bone cells; and SimpliDerm, a pre-hydrated HADM designed to repair or replacement of damaged or inadequate integumental tissues. Further, the company provides contract manufacturing services for various products to corporate customers. It sells its products to hospitals and other healthcare facilities through its direct sales force, commercial partners, and independent sales agents. The company was incorporated in 2015 and is headquartered in Silver Spring, Maryland.
Aziyo Biologics，Inc.是一家再生醫學公司，專注於再生醫療產品的開發，以滿足植入式電子設備/心血管、矯形/脊柱修復和軟組織重建市場。它提供CanGaroo，它將信封與抗生素結合在一起，旨在降低電子設備手術植入後的感染風險。該公司還提供心血管產品，如用作心臟內補片或組織修復的質地的ProxiCor；用於新生兒和嬰兒修復心包結構的Tyke；以及用於修復或重建周圍血管的補丁材料VasCure，包括供心血管、血管和普通外科醫生使用的頸動脈、腎、髂骨、股動脈和脛骨血管。此外，它還提供Fibre VBM、Vibone和OsteGro V，這是一種從人體組織衍生的同種異體骨移植，旨在保護和保存天然骨細胞；以及Simpliderm，一種預水HADM，旨在修復或替換受損或不充分的外皮組織。此外，公司還為企業客户提供各種產品的代工服務。它通過其直銷隊伍、商業合作伙伴和獨立銷售代理向醫院和其他醫療機構銷售其產品。該公司成立於2015年，總部設在馬裏蘭州的銀泉。
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
接受Genocea生物科學日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Genocea Biosciences和相關公司的最新新聞和分析師評級的每日簡要摘要。